State-of-art Technologies for New Level of Insights in Precision Medicine
High-fidelity Data Driven by Innovations Spanning the Metabolomics Workflow
The desire for a healthier life motivates us to apply metabolomics to complex problems in precision medicine. This unique perspective of the omics sciences allows everyone to study their own health at the molecular level.
The result of gene-environment interaction is ultimately reflected in our physical state, known as phenotypes, with metabolites being the most closely related. We are committed to solving major medical challenges across the healthcare continuum, such as early diagnosis, high-risk screening, and treatment monitoring, through comprehensive and integrated analysis of these small molecules in blood. The metabolic models developed will be translated into a series of accurate, non-invasive, and simple IVD tests using AI and metabolomics.
Our flagship product MDTargTM (Multiple Disease Target) is a pan-disease detection test targeting cancers and cardiovascular diseases. It is a next-generation liquid biopsy fueled by breakthroughs in metabolomics and machine learning.
Recent data show that lung cancer remains the leading cause of cancer mortality. Screening and early diagnosis are the key to early intervention to improve outcomes. Low-dose spiral CT (LDCT) is the primary screening tool for lung cancer, but it has a high false-positive rate.
According to the most recent cancer data in China, there were 397,000 new cases of gastric cancer in 2016, accounting for nearly half of all global gastric cancer patients. The incidence of gastric cancer is much higher in men than in women. Gastroscopy is the primary screening method, which is invasive, inconvenient, and uncomfortable.
Colorectal cancer is the second most common cancer in China, and the incidence rate is increasing each year. The incidence rate is higher in urban areas, and approximately 90% of patients are already in the middle or late stages when diagnosed. The standard screening method is colonoscopy, but compliance is low because of its invasiveness and inconvenience.
In systems biology, metabolomics provides rich information at the early stage of disease or during treatment monitoring, paving the way for a new direction in clinical research.
The change in metabolic levels has already occurred in the early stage of diseases. As molecules closest to phenotypes, metabolomics can predict disease even before clinical symptoms.
The change in metabolic levels has already occurred in the early stage of diseases. As molecules closest to phenotypes, metabolomics can predict disease even before clinical symptoms.
Insights provided by the powerful multi-omics data help us to describe the precise changes of metabolic pathway under specific genetic regulation related to metabolic phenotype.
Insights provided by the powerful multi-omics data help us to describe the precise changes of metabolic pathway under specific genetic regulation related to metabolic phenotype.
Metabolomics is used to understand the disease interference network and to find the prognosis evaluator, to form evaluation basis in treatment improvement such as effect evaluation and adverse event intervention.
Metabolomics is used to understand the disease interference network and to find the prognosis evaluator, to form evaluation basis in treatment improvement such as effect evaluation and adverse event intervention.
Prognostic analysis is prediction on disease endpoints, which is useful when making clinical decisions. Metabolomics may help researchers discover metabolites connecting to disease severity, enabling prediction of disease recurrence.
Prognostic analysis is prediction on disease endpoints, which is useful when making clinical decisions. Metabolomics may help researchers discover metabolites connecting to disease severity, enabling prediction of disease recurrence.
Metanotitia’s proprietary metabolomics platform for high-throughput data collection and analysis, provides comparable, interpretable, and high-quality metabolomics data, laying a solid foundation for basic research and scientific research transformation.
Surveilled Machine Performance
Environment Control
Real-time QC Analytics
Unique Identification Tag
QR Code Technology
Real-time Database Synchronization
Longitudinal Management of Various Sample Types
MS and MS/MS Data for 8000+ Metabolites
Self-built and Actively Expanding
Cover Multiple Species
Comprehensive Metadata
One-stop data processing workflow
Independent IP of algorithms and database
Solution for large-scale analysis
Proprietary High-throughput Annotation Software
Integrated UlibMSandPublic databases
Annotation by Professionals
Experienced Research Team
Founded in 2018, Metanotitia Inc. is dedicated to transform treatment decisions and outcomes by delivering clinically actionable diagnostics, specializing in offering one-stop solutions by leveraging the power of metabolomics. The founding team transferred the top-tier technology and more than 20 years of scientific research experience in metabolomics from Germany to Shenzhen, China, and is committed to building and upgrading theProfMet metabolomics R&D platform. We are dedicated to combine high-quality human metabolome data with AI advances to answer clinical questions.
Are you looking to establish strategic collaboration or partnership opportunity in cancer research with an innovative and progressive research company? We are interested in collaborations with leading researchers, institutions, and facilities with proven track records. Contact us or leave your message below.
Service hotline
0755-26921231Address
